2025-05-27 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc (TMDX), incorporating the provided data.

**Report on Transmedics Group Inc (TMDX)**

Transmedics Group Inc. is a medical technology company pioneering a novel approach to organ preservation for transplantation.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (TMDX):** 239.21%
*   **Cumulative Return (VOO):** 50.81%
*   **Absolute Divergence:** 188.4
*   **Relative Divergence:** 71.3 (Indicates TMDX's outperformance is in the upper range of its historical divergence from the S&P 500)

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2019-2021  | -4.0%  | 63.4%  | -57.0% | 0.0  | 0.7    |
| 2020-2022  | 140.0% | 68.3%  | 134.0% | 0.0  | 2.1    |
| 2021-2023  | 95.0%  | 69.4%  | 79.0%  | 0.3  | 2.7    |
| 2022-2024  | 147.0% | 82.8%  | 130.0% | 0.3  | 2.1    |
| 2023-2025  | 120.0% | 82.8%  | 93.0%  | 0.5  | 4.2    |

*   **Analysis:** TMDX has significantly outperformed the S&P 500. The high Alpha values indicate substantial excess returns relative to the market. However, high MDD (Maximum Drawdown) values point to significant volatility and risk. Increasing Beta values could indicate a trend of the stock becoming more sensitive to market movements.

**2. Recent Price Action**

*   **Current Price:** 124.25
*   **Previous Close:** 123.34
*   **Change:** 0.74
*   **5-day Moving Average:** 123.14
*   **20-day Moving Average:** 108.17
*   **60-day Moving Average:** 85.53

*   **Analysis:** The stock is trading above all three moving averages, indicating a strong upward trend.  The fact that the 5-day average is above the 20-day and 60-day averages reinforces this bullish signal. The modest positive change since the previous close suggests continued upward momentum.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 85.12 (Overbought)
*   **PPO:** 0.0687
*   **Hybrid Signal:** Cash 0%, Buy 80% of cash (1 share - Caution - MRI: 0.37)
*   **20-day Relative Divergence Change:** 3.3 (Positive - short term increase)
*   **Expected Return:** 39.8% (Long-term, vs. S&P 500)

*   **Analysis:** The RSI indicates the stock is overbought, which could suggest a potential pullback. The PPO being positive further reinforces bullish trend. Despite the overbought RSI, the MRI suggests a low-risk environment. The hybrid signal recommends buying, but with caution. Recent increase in 20-day divergence shows short term positive trend. The expected return is very high, suggesting strong growth potential over the long term.

**4. Recent News & Significant Events**

*   **[2025-05-27]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-26]:** Analyst discussions on recent performance and outlook.
*   **[2025-05-23]:** Notable stock volatility.
*   **[2025-05-24]:** Mixed risk and opportunity assessment by market experts.

*   **Analysis:** The news indicates that the stock is currently subject to significant market attention and volatility. This highlights the importance of monitoring news and company announcements closely.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-05-08 | 0.70 | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |
| 2024-04-30 | 0.35 | 0.03256      |

*   **Analysis:** The company has consistently beaten EPS estimates in recent quarters, indicating strong financial performance.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |
| 2024-03-31 | $0.10B  | 61.91%        |

**Capital and Profitability**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-03-31 | $0.27B   | 9.64%   |
| 2024-12-31 | $0.23B   | 3.00%   |
| 2024-09-30 | $0.21B   | 2.01%   |
| 2024-06-30 | $0.19B   | 6.42%   |
| 2024-03-31 | $0.16B   | 7.65%   |

*   **Analysis:** Revenue has been steadily increasing, demonstrating the company's growth. Profit margins are very high, indicating strong operational efficiency. Equity is also increasing, and ROE is showing positive momentum, suggesting improving profitability.

**7. Overall Assessment**

TMDX has demonstrated significant outperformance compared to the S&P 500, driven by strong financial performance and high growth potential.  The company's recent earnings beats, increasing revenue, and high profit margins are all positive indicators. However, the stock exhibits significant volatility, as evidenced by the high MDD and recent news headlines.

**Key Considerations:**

*   **Overbought Condition:** The high RSI suggests the stock may be due for a correction.
*   **Volatility:** Investors should be prepared for potential price swings.
*   **Long-Term Potential:**  The high expected return indicates that TMDX could be a promising long-term investment, but with careful monitoring.
*   **News Monitoring:**  Given the recent volatility and analyst discussions, staying informed about company news and industry developments is crucial.

**In summary, TMDX presents an intriguing investment opportunity with high growth potential, but also requires a high degree of risk tolerance and diligent monitoring.**
